Astex ranked in the top 20 of The Sunday Times ARM Tech Track 100
Cambridge, UK - Astex Technology, the fragment-based drug discovery company, is ranked 12th in the Sunday Times ARM Tech Track 100 league of Britain's fastest growing technology companies, published Sunday 28th September. Astex is one of only a small group of biotechnology companies to have made it onto the annual ARM Tech Track 100 since the list was first compiled in 2001. The company is ranked as the fastest growing technology company in the Cambridge area, long-renowned for the development of innovative technology companies.
This year Astex has signed major deals with pharmaceutical companies Schering AG, to discover novel drugs to treat cancer, and AstraZeneca, to develop drug candidates for Alzheimer's disease. Astex also has drug discovery deals with Aventis, Mitsubishi Pharma Corporation and Fujisawa Pharmaceutical Co., Ltd. The company's annual sales growth in the period 2000-2002 was more than 170%.
"We are really pleased to appear in this prestigious listing of Britain's top technology companies. This achievement confirms the talent and commitment of Astex's team of professionals and is a tribute to everyone in the company," stated Mr. Timothy Haines, CEO of Astex.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.